SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Dated: September 10, 2003

Commission file number 0-21392

AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)

ENGLAND
(Jurisdiction of Incorporation or organization of Issuer)

7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

[X] Form 20-F [ ] Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

[ ] Yes [X] No

Attachment:

Material Events

(a) Amarin Corporation acknowledges receipt by Watson Pharmaceuticals of Final FDS Approval of Final FDA approval for generic Glucotrol XL (r) 5 mg tablets.

This report on Form 6-K is hereby incorporated by reference in the registration statement on Form F-3 (Registration Statement No. 333-12642) of Amarin Corporation plc and in the prospectus contained therein, and in the Registration Statement on Form F-3 (Registration No. 333-13200) of Amarin Corporation plc and in the prospectus contained therein, and this report on Form 6-K shall be deemed a part of each such registration statement from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AMARIN CORPORATION PLC

By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer

Date: September 10, 2003

Index to
Exhibits

Exhibit (a)

Contact:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com

AMARIN CORPORATION ACKNOWLEDGES RECEIPT BY WATSON PHARMACEUTICALS OF FINAL FDA APPROVAL FOR GENERIC GLUCOTROL XL(r) 5mg TABLETS

Tentative ANDA approval received by Watson for Glucotrol XL 10mg tablets

LONDON, United Kingdom, September 10, 2003 - Amarin Corporation plc (NASDAQ: AMRN) today confirmed that Watson Pharmaceuticals, Inc. (NYSE: WPI - News), a leading specialty pharmaceutical company had received approval on its Abbreviated New Drug Application (ANDA) for 5mg glipizide extended-release tablets from the United States Food and Drug Administration (FDA). Additionally, Watson has received tentative approval for the 10mg strength.

As previously announced, Amarin Development AB, Amarin's Swedish subsidiary developed the generic formulation of Watson's glipizide extended release tablets and Amarin is entitled to a royalty on all sales of the generic formulation as part of its agreement with Watson Pharmaceuticals. Glipizide extended release tablets are marketed in the United States under the trade name Glucotrol XL(r) by Pfizer, Inc.

Glucotrol XL (glipizide extended release tablets) is indicated as an adjunct to diet for the control of hyperglycemia in patients with type-2 diabetes.

Amarin Corporation plc is a specialty pharmaceutical company focused on neurology. The Company plans to become a leader in these therapeutic categories by providing innovative products and solutions that address significant unmet medical needs. Amarin has eleven pharmaceutical products on the US market along with a development pipeline that includes two late-stage candidates: Zelapar (tm) (selegiline orally disintegrating tablets), for Parkinson's disease and LAX-101, a proprietary compound for Huntington's Disease.

For press releases and other corporate information, visit our website at http://www.amarincorp.com.

Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company's actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialization, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The Company assumes no obligation to update information on its expectations.